Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of LG203003 in healthy adults and patients with non-alcoholic fatty liver disease (NAFLD)

Next Previous
Search
Trial Profile

A phase I trial of LG203003 in healthy adults and patients with non-alcoholic fatty liver disease (NAFLD)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LG 203003 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions
  • Sponsors LG Chem

    • Most Recent Events

    • 18 Jul 2022 New trial record
    • 14 Jul 2022 According to a LG Chem media release, LG203003 received clearance from the U.S. Food and Drug Administration (FDA) in March 2022 for the Investigational New Drug (IND) application to conduct this trial. The first subject has been enrolled and was dosed on July 6, 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top